INTRODUCTION
Prion diseases or transmissible spongiform encephalopathies (TSE) are characterized by progressive degeneration of neurons in the central nervous system (CNS) accompanied by the accumulation of an abnormal, insoluble and protease-resistant conformer (PrP Sc ) of the host-encoded prion protein (PrP C ) (Prusiner, 1998) . Although it is clearly established that PrP Sc plays a key role in the origin and transmission of TSEs, it remains to be determined how the disease-specific prion protein exerts its harmful effects on the neurons (Aguzzi et al., 2008) .
There is circumstantial evidence that a fraction of PrP C can be localized in the cytosol of various cultured cells and brain neurons. This evidence is partly based on the finding that inhibition of the proteasome induces accumulation of an abnormal, unglycosylated form of PrP in the treated cultures. Several authors have proposed that PrP C can enter the endoplasmic reticulum (ER)-associated protein degradation or ERAD pathway (Ma & Lindquist, 2001; Yedidia et al., 2001) , although normally at low efficiency (Rane et al., 2004; Ashok & Hegde, 2008) and be retrotranslocated into the cytosol where it can be degraded by cytosolic, primarily proteasomal, proteases (Wang et al., 2005) . It has been further proposed that enhanced accumulation of cytosolic PrP might be detrimental to the neurons, and that perturbation of PrP metabolism through the proteasomal pathway could play a pathogenic role in prion diseases (Ma & Lindquist, 1999; Yedidia et al., 2001; Grenier et al., 2006; Wang et al., 2006) . For other authors, however, these observations have arisen essentially from experimental settings (Drisaldi et al., 2003; Fioriti et al., 2005) . In addition, PrP was found in the cytosol in subpopulations of neurons in several areas of normal brain (Mironov et al., 2003) , and a neurotoxic activity of cytosolic PrP C could not be demonstrated in various neuronal cell systems (Roucou et al., 2003; Fioriti et al., 2005) . Of note, the impact of such controversies seems to be limited as long as there is no clear evidence that cytosolic PrP increases during the course of a natural prion disease . With this in mind, the recent findings that abnormal PrP can accumulate in the cytosol of infected cells in culture, form aggresome-like structure and cause proteasome malfunction are of the utmost interest (Kristiansen et al., 2005 (Kristiansen et al., , 2007 . However, the existence of free, cytosolic PrP Sc and the formation of aggresomes in neurons within prion-infected nerve tissues remains poorly documented to date.
In this study, we investigated the effects of proteosomal impairment on both PrP C synthesis and PrP Sc formation in the same neuronal cells, expressing PrP from the endogenous gene. The CAD cell line was used here as the main model system. These cells derive from mouse brain neurons, and on serum deprivation exhibit a differentiated phenotype with major ultrastructural and electrophysiological features of CNS neuronal cells (Qi et al., 1997; Wang & Oxford, 2000) . We found that, whilst CAD cells did accumulate abnormal PrP following treatment with proteasome inhibitors, the formation of aggresomes containing aggregated PrP with true PrP Sc characteristics was only a feature of prion-infected cultures.
METHODS
Antibodies and reagents. Monoclonal antibodies (mAbs) SAF32 (specific for the epitope aa 79-89; Féraudet et al., 2005) and ICSM18 (aa 143-153; Beringue et al., 2004; Khalili-Shirazi et al., 2005) were used to detect PrP C . mAb 3F4 (aa 109-112; Dako) was used to detect the 3F4 epitope-tagged mouse PrP (Scott et al., 1992) . mAbs Sha31 (aa 145-152; Féraudet et al., 2005) and ICSM33 (aa 91-110; KhaliliShirazi et al., 2007) were used to detect PrP Sc by Western blotting or immunocytochemistry. A polyclonal antibody (pAb) generated against aa 14-27 of mouse PrP (Stewart et al., 2001 ) was used to detect the N-terminal signal peptide. Rabbit pAbs anti-giantin and anti-vimentin were purchased from Abcam. pAbs anti-c-tubulin and anti-20S proteasome were from Sigma and BIOMOL, respectively. mAb anti-Hsp70/Hsc70 was from Stressgen. Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor 568-conjugated goat anti-rabbit IgG were purchased from Molecular Probes. Tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse IgG1 and fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG2b were from Caltag/Invitrogen. ALLN (N-acetyl-LeuLeu-norleucinal), MG132 (Z-Leu-Leu-Leu-al), cyclosporine A (CsA), staurosporine and nocodazole were from Sigma-Aldrich. The proteasome inhibitor bortezomib (Velcade), also referred to as PS341, was a generous gift of the Janssen-Cilag Laboratories.
Cell culture and drug treatment. Mouse neuronal CAD cells (Qi et al., 1997) have been cultivated routinely in our laboratory (DandoyDron et al., 2003) . The cells were cultivated in Opti-MEM (Invitrogen) supplemented with 10 % fetal calf serum (FCS). Differentiated cells were induced by cultivation in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (BioWhittaker) supplemented with 0.5 % FCS. CAD cells were treated with proteasome inhibitors for 16-18 h at a concentration of 25 mM ALLN, unless stated otherwise. For experiments using nocodazole, cells were incubated for 2 h with nocodazole at a concentration of 2 mM prior to co-treatment with 25 mM ALLN for 18 h. PC12 cells were cultivated on coated plates in DMEM (Invitrogen) with 10 % horse serum and 5 % FCS. N2A cells were cultivated in DMEM and 10 % FCS. Primary cultures of cortical neurons from Swiss mice embryos were established as described previously (Dandoy-Dron et al., 2003) . For proteasome impairment, neurons were incubated with 10 mM ALLN or 6.25 mM MG132 for 10 h. Treatments with drugs or vehicle only were started 24 or 48 h after plating for the cell lines and 1 week after establishment of the neuron culture.
Transfection of CAD cells. CAD cells were transfected with the plasmid pBC12/CMV/WT moPrP expressing the 3F4-tagged PrP under the control of the human cytomegalovirus promoter (Lehmann & Harris, 1995) using Lipofectamine Plus (Invitrogen), as described previously (Dandoy-Dron et al., 2006). Transfected cells were incubated with proteasome inhibitors 1 or 2 days after transfection and harvested after 24 h of treatment.
Cellular lysates and protease digestion. Cells were lysed in TL1 buffer [0.5 % Triton X-100, 0.5 % sodium deoxycholate, 50 mM Tris/ HCl (pH 7.4)] and lysates were clarified by centrifugation at 400 g for 2 min. The protein concentration in the lysates was determined by using a Micro BCA assay (Pierce). For some experiments, lysates were ultracentrifuged at 100 000 g for 1 h at 4 uC either directly or after a 30 min incubation with l % sarkosyl on ice. To test the proteinase K (PK) sensitivity of PrP C from ALLN-treated cultures, 3610 6 cells were pelleted at 4 uC and solubilized in 100 ml TL1 buffer. One hundred micrograms of protein in 20 ml TL1 buffer was digested at 37 uC for 30 min with 0.25-4 mg PK (mg protein) 21 (i.e. from 1.5 to 20 mg PK ml 21 ). PMSF (2 mM) and 1 vol. 26 denaturing sample buffer were added to terminate the reaction.
Prion infection and PrP
Sc detection. Brains from C57Bl6 mice inoculated with strain 139A or 22L mouse-adapted strains (originating from the R. Carp Laboratory, Staten Island, NY, USA) were homogenized in 5 % glucose adjusted to 20 % (w/v) and kept frozen at -80 uC until use. CAD cells were plated 24 h before incubation with sonicated brain homogenate (0.5 % final concentration) in culture medium for 2 days. Cultures were washed twice with PBS and cultivated as described for uninfected cells. To test for the presence of PrP Sc , 5610 6 cells were washed twice with cold PBS and covered with 1 ml TL1 buffer for 10 min at 4 uC. Lysates were clarified by centrifugation at 400 g for 2 min and the concentration of proteins was determined. One hundred micrograms of protein was digested in 200 ml TL1 buffer with 16 mg PK (mg protein) 21 (i.e. 8 mg PK ml 21 ) for 1 h at 37 uC, and 4 mM Pefabloc (Invitrogen/Gibco) was added and the samples precipitated with 4 vols cold methanol. Pellets were recovered by centrifugation at 13 000 g for 30 min, resuspended in sample buffer and analysed by Western blotting using mAb Sha31.
Western blotting. Samples in denaturing Laemmli buffer were run on NuPAGE 12 % Bis-Tris gels from Invitrogen in MES buffer. Proteins were transferred to nitrocellulose membrane (Bio-Rad) using a Semi-dry Trans-Blot Cell System (Bio-Rad). Protein Standards from Bio-Rad were used as molecular mass markers. Membranes were incubated with antibodies in the presence of 0.5 % blocking reagent (Roche) in TBST [10 mM Tris/HCl (pH 7.4), 150 mM Nacl and 0.1 % Tween 20] except for Sha31, which was used at a 1 : 30 000 dilution without blocking reagent. The proteins were revealed by enhanced chemiluminescence using a biochemoluminescent detection system (Roche) and signals were quantified using GeneGnome (Syngene).
Immunocytochemistry and confocal microscopy. Cells were cultivated on coated eight-chamber tissue culture glass slides (BD Biosciences; 4610 3 cells cm 22 ) and treated with proteasome inhibitors 1 or 2 days after plating. Cells were fixed with 4 % paraformaldehyde and permeabilized with 0.1 % Triton X-100 before treatment with guanidium thiocyanate at 3.5 M to reveal PrP Sc epitopes when needed. mAbs SAF32 and ICSM33 (1 mg ml 21 ) and anti-giantin pAb were used at a 1 : 300 dilution. pAbs anti-vimentin, anti-20S proteasome and anti-c-tubulin were used following the recommendations of the suppliers. Antibodies were revealed with Alexa Fluor-conjugated secondary antibodies, except for mAb antiHsp70 used at 1 : 75 dilution, which was revealed with TRITCconjugated anti-mouse IgG1, and ICSM33, which was detected with FITC-conjugated anti-mouse IgG2b in this experiment. Mitochondria were detected using MitoTracker Red from Invitrogen applied to the cells at a 1 : 3000 dilution for 30 min at 37 uC before washing and fixation with paraformaldehyde. Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI) and the coverslips were mounted on slides using Fluoromount G anti-fading agent (FluoProbes). Images were acquired with a Zeiss Axiovert 200M microscope and a IP: 54.70.40.11
On: Sat, 12 Jan 2019 20:28:11 CCD CoolSNAP HQ camera (Roper Scientific) driven by MetaVue Imaging System software (Molecular Devices/MDS Analytical Technologies). Confocal analysis was carried out with a Zeiss LSM510 META microscope linked to an AxioCam HRm camera. Acquisition and treatment of the images were carried out by using CLSM 510 software. Multiple optical planes in the axial (Z) direction were collected at intervals of 1 mm and three-dimensional images were reconstructed.
RESULTS
Proteasome inhibition leads to the accumulation of 26 kDa PrP species in CAD cells CAD cell cultures, either untransfected or expressing 3F4 epitope-tagged mouse PrP, were treated with the potent proteasome inhibitor ALLN. Western blot analysis showed that, in ALLN-treated cultures, the proportion of the 26 kDa band corresponding to unglycosylated PrP species increased about fivefold relative to the other PrP glycoforms, in both untransfected and transfected cells (Fig. 1a,  b ). An accumulation of 26 kDa PrP species was also observed when untransfected cells were treated with two other proteasome inhibitors, MG132 and PS341 (Fig. 1c) , indicating that proteasomal rather than other cytosolic protease activities were primarily involved in this effect. These results formally established that upregulation of PrP expression is not required for this effect to occur and does not amplify it.
CsA, a fungal peptide that specifically inhibits the cyclophilin protein family, has been reported to induce abnormal accumulation of a 26 kDa species in cells overexpressing tagged PrP (Cohen & Taraboulos, 2003) , presumably by preventing ER cyclophilins from rescuing misfolded PrP molecules, making them eligible for retrotranslocation. Treatment of untransfected CAD cells with this compound also led to an accumulation of a 26 kDa PrP species (Fig. 1c) . In contrast, neither treatment with staurosporine, a pro-apoptotic agent nor a heat shock of 45 u C for 30 min (Dandoy-Dron et al., 2006) produced accumulation of PrP, indicating that stress conditions leading to neuronal cell death were not sufficient by themselves to explain the phenomenon (Fig. 1c ).
Treatment with ALLN or MG132 also induced the accumulation of 26 kDa PrP in other non-transfected neuronal cells (PC12 and N2A) and in mouse cortical neurons (Fig. 2a, b) . In primary cultured cortical neurons from wild-type mice, the increase in the 26 kDa form occurred even at relatively low doses of inhibitor. CAD cells can be differentiated by cultivation under serum starvation. Treatment of such cultures ( Fig. 2c) with ALLN or MG132 again led to an increased level of 26 kDa PrP (Fig. 2b) . Taken together, these results showed that overaccumulation of 26 kDa PrP species (hereafter designated PrP 26K ) upon proteasome impairment may be a general feature of dividing or post-mitotic neuronal cells.
PrP 26K induced in CAD cells by proteasome inhibition is detergent-insoluble and weakly protease-resistant
To characterize further the PrP 26K in CAD cells, ALLNtreated cultures were lysed in the presence of 0.5 % Triton X-100 and post-nuclear supernatants were centrifuged at high speed either directly or after incubation with 1 % sarkosyl. Supernatants and pellets were analysed by Western blotting (Fig. 3a) . Strong PrP 26K signals were detected only in the pellet fractions of treated cells, indicating that this PrP species is essentially detergentinsoluble. CAD cell lysates were also subjected to proteolysis with PK before Western blot analysis ( Fig.  3b-d) . Under mild PK treatment that was sufficient to eliminate the regular PrP C , PrP with some degree of protease resistance was detected in ALLN-treated cultures, and this PK-resistant form strictly co-migrated with PrP 26K , i.e. was not truncated (Fig. 3c) . When an antibody directed against the structured core of the protein was used, an additional protease-resistant PrP species with a molecular mass of 19 kDa became detectable (Fig. 3d) , which comigrated with the PK-resistant core of PrP Sc in infected cells (see below). Taken together, these results showed that PrP 26K in CAD cells, expressing endogenous PrP, and the abnormal PrP 26K species described in cells overexpressing tagged PrP (Yedidia et al., 2001) share very similar features.
Subcellular localization of PrP in proteasomeimpaired CAD cells
The unglycosylated PrP form accumulating in PrP-overexpressing cell models under proteasome inhibition has been proposed by some authors to be immature molecules that have escaped translocation into the ER, as they apparently retained their signal peptide (Stewart et al., 2001) . To address this important issue, we used antibodies directed against the N-terminal signal peptide. We reproducibly failed to detect ALLN-induced PrP 26K in CAD or N2a cells (Fig. 3e, f) . This indicated that the signal peptide was essentially removed from ALLN-induced endogenous PrP 26K , suggesting that this species was Proteasome inhibition and PrP Sc aggresomes in CAD cells translocated into the ER. It should be noted that this was not the case in cell cultures that overexpressed 3F4 epitopetagged PrP, possibly due to the inability of the ER to process excessive levels of this form of PrP.
Next, we examined the subcellular localization of PrP in control and ALLN-treated CAD cells by immunofluorescence microscopy ( Fig. 4a-f ). Whilst the PrP staining pattern was consistent with the expected cell-surface expression of the protein, the ALLN-treated cells showed an additional strong intracellular PrP signal, which colocalized with giantin, a usual marker of the Golgi apparatus ( Fig. 4d-f) . Such a prominent Golgi-associated PrP staining pattern was consistently observed following proteasome inhibition of CAD cells by ALLN or MG132, using three different anti-PrP mAbs (data not shown). This suggested that proteasome inhibitors may affect the trafficking or turnover of PrP within the Golgi apparatus in CAD cells. However, we failed to obtain clear evidence for cytosolic PrP labelling in proteasome-impaired cells.
Accumulation of PrP 26K does not alter the glycoform profile or level of PrP Sc in prioninfected cells
We sought to determine whether the presence of abnormal PrP 26K in proteasome-impaired cells would influence the formation of highly PK-resistant PrP Sc when the cells were infected. In CAD cells, a newly introduced infectable cell system able to propagate several mouse-adapted prion strains, infection establishes from the very first postinfection passages, as assessed by de novo accumulation of PK-resistant PrP Sc , and persists for at least 6 months of cultivation (unpublished data). Cell cultures steadily infected by the 139A strain were treated for 1 day with ALLN or MG132. The level of PrP 26K increased four-to sixfold in infected cultures following proteasome inhibition, similar to that in uninfected cultures (Fig. 5a ). However, after PK treatment, neither the relative level of the unglycosylated species nor the intensity of the whole PrP signal differed between the treated and untreated cultures (Fig. 5b) . Similar results were obtained for cells infected with the 22L scrapie strain (Fig. 5c) . ALLN treatment induced a similar mortality in infected and uninfected cultures, i.e.~15 and 65 % after 24 and 48 h exposure, respectively (data not shown). At a lower ALLN concentration, CAD cells can be cultivated for several days with minimal toxicity. Strain 139A-and 22L-infected cells were cultivated for 4 days with 10 mM ALLN, thus allowing more extensive replication of the prion in the presence of the inhibitor. Despite an increase in the PrP 26K species at the same level as in cultures treated with higher doses of inhibitor, the amount and glycoform profile of PrP Sc in ALLN-treated and control cultures were again quite similar (Fig. 5d) .
Proteasome impairment induces the formation of large aggresomes in infected CAD cells
The subcellular distribution of PrP Sc in infected, ALLNtreated cultures was examined by immunofluorescence microscopy. Under standard conditions of fixation and permeabilization, in which the bulk of PrP Sc escapes labelling by anti-PrP antibodies, we observed a PrP staining mostly associated with the Golgi apparatus (Fig. 4j-l) , essentially similar to that in uninfected cells (Fig. 4d-f) . To obtain selective labelling of PrP Sc , the following conditions were selected: (i) a short treatment with 3.5 M guanidium thiocyanate was carried out to expose PrP Sc -specific epitopes and reduce PrP C labelling; (ii) the ICSM33 antibody was used to avoid residual PrP C labelling, as it elicits strong immunofluorescence with partially denatured PrP Sc while producing a very weak PrP C signal (Paquet et al., 2007) ; and (iii) the cells were seeded at low density to prevent the formation of tight cellular junctions, as these structures tend to be strongly decorated with PrP antibodies (Viegas et al., 2006) . Under this experimental setup (Fig. 6) , about 75 % of the cells in infected cultures showed variable-sized spots with high fluorescence intensity (Fig. 6e, m) , whereas uninfected cultures remained unlabelled (Fig. 6a, i ).
Confocal analysis indicated that the vast majority of these PrP Sc -positive spots were intracellular (Fig. 7c, d) . In a number of positive cells, the spots were clearly individualized over the Golgi area; however, in about one-third of them, spots with intense staining were also found in a perinuclear region that partially overlapped the Golgi apparatus (Figs 6g, o and 7a) . The most striking difference in ALLN-treated cultures compared with non-treated ones was the much higher proportion of cells showing a large, intense PrP staining condensed in structures surrounded (Fig. 7b,  d ) fit well with these observations. Indeed, confocal microscopy analysis showed that, in such areas, giantin and PrP Sc labelling tightly co-regionalized but did not really co-localize, as the fluorescence intensity profiles of giantin and PrP Sc staining were not superimposed (Fig. 7c,  d) . Moreover, three-dimensional modelling of the data (Fig. 7e-g ) provided evidence that the PrP Sc -positive spots in the juxtanuclear position were imbricated with Golgian structures in untreated cells (Fig. 7g) , whereas in treated cells they often appeared agglomerated into larger, roughly spherical structures of several microns in width, which themselves were surrounded by Golgian cisternae (Fig. 7h ).
Several lines of evidence supported the view that the large juxtanuclear PrP
Sc deposits induced by proteasome inhibition did correspond to PrP Sc -containing, bona fide aggresomes: (i) PrP Sc labelling co-localized with vimentin, known usually to form a cage surrounding the aggresome (Fig. 8a-c) ; (ii) large PrP Sc aggregates were accumulated at the microtubule organization centre (MTOC), i.e. around the centrosome, identified by anti-c-tubulin antibodies (Fig. 8g-i) , and co-treatment with nocodazole, which disrupts the microtubule network connected to the MTOC, impaired the formation and/or disrupted PrP Sc aggresomes ( Fig. 8t; compare with Fig. 8s) ; (iii) as observed for most of the aggresomal structures described, the PrP Sc aggresome recruited 20S proteasome and Hsp70 (Fig. 8j-l and p-r) and the density of mitochondria was greatly increased around the aggresome (Fig. 8m-o) . It should be noted that the local concentration of these latter markers did not occur in infected cells left untreated with proteasome inhibitors (data not shown) and there was no clear-cut formation of a vimentin cage, even for the minority of cells that displayed small, individual, non-coalescent aggregates in a juxtanuclear position (Fig. 8d-f) . Therefore, inhibition of the proteasome appeared to be required for the formation of large, well-defined PrP Sc aggregates displaying the classical features of aggresomes.
DISCUSSION
In the present study, we have reported the effects of proteasome inhibition on the biogenesis of PrP in uninfected and infected CAD neuronal cells, a mouse cell line recently recognized as being a robust system for prion propagation in culture (Mahal et al., 2007 and this study) . We found that, following treatment with three different proteasome inhibitors, CAD cells accumulated an abnormal form of PrP, here termed PrP 26K , which co-migrated with PrP C unglycosylated species, and was detergentinsoluble and resistant to mild PK digestion. This species, also detected in PC12 and N2a cells, appeared to be similar to that described in earlier studies (Ma & Lindquist, 2001; Cohen and Taraboulos, 2003; Wang et al., 2005) . However, we also observed clear accumulation of PrP 26K in primary cultured cortical neurons derived from wild-type mice and treated with ALLN or MG132, which is in contrast to earlier findings in cerebellar neurons (Drisaldi et al., 2003) . The reason for this discrepancy is unclear, although it is conceivable that different neuron subpopulations may be variably susceptible to these compounds. Taken together, our findings provide firmer evidence that impairment of Another controversial issue in the literature is the mechanism underlying the accumulation of the abnormal PrP 26K form in the cytosolic compartment. In CAD cells, we failed to observe accumulation in the cytoplasm following proteasome impairment. The most obvious modification was a dramatic increase in the PrP signal in the Golgi compartment. Incidentally, intense perinuclear PrP staining associated with the Golgi apparatus has also been reported by other authors, although in cell systems that overexpressed exogenous PrP (Ma & Lindquist, 2001; Yedidia et al., 2001) . Taken together, these observations support the unorthodox view that some failure of the glycosylation of PrP C and/or impaired trafficking through the Golgi apparatus could contribute to the generation of the insoluble PrP 26K form. Importantly, we found no evidence for the presence of an uncleaved signal peptide on the PrP 26K molecules produced in ALLN-treated CAD and N2A cells. The absence of a detectable signal peptide on insoluble PrP C argues that it was essentially mature protein, rather than a neo-translated protein, that failed to achieve ER translocation as proposed for cells overexpressing tagged PrP driven by a heterologous promoter (Drisaldi et al., 2003; Fioriti et al., 2005) .
PrP-containing aggresomes have been observed in cells expressing mutant PrP (Singh et al., 2005) or with enforced expression of wild-type PrP directly to the cytosol (Goggin et al., 2008) , and in cells expressing tagged and/or mutated, mature PrP from a strong promoter and treated with epoxomicin, ALLN or CsA (Ma & Lindquist, 2001; Cohen & Taraboulos, 2003; Mishra et al., 2003) . However, no aggresome formation appears to occur following proteasome inhibition in cells that express wild-type, endogenous PrP (Kristiansen et al., 2005 and this study). Upon prion infection, however, untreated CAD cells showed relatively large PrP aggregates throughout their cytoplasm, mainly in a juxtanuclear region for a proportion of cells. This observation may not be unique to the cell system studied here. Indeed, looking at the literature, we found images showing a prominent juxtanuclear deposition pattern in three recent studies involving infected N2A cells, which was either unaccounted for by the authors (Kristiansen et al., 2005; Veith et al., 2009) or interpreted as intranuclear inclusions (Mangé et al., 2004) . Under proteasome inhibition, this phenomenon of juxtanuclear deposition appeared to be dramatically amplified, leading to the formation of typical aggresomal structures. This would suggest that at least some of the PrP Sc cytoplasmic aggregates are accessible to degradation through the proteasome pathway. Cytosolic PrP Sc might somehow be deposited at the MTOC as pre-aggresomal structures, so that inhibition of the proteasome would result in the formation of large-sized aggresomes, as documented for other misfolded proteins (García-Mata et al., 1999, 2002) .
The question arises, however, of whether and how such a scenario could apply to PrP Sc , of which the known deposition sites are the cell surface or the endocytic compartment, where the conversion process may take place (Campana et al., 2005) . It should be pointed out that our findings overall are in good accordance with those of Kristiansen et al. (2005) , who reported the formation of PrP Sc -containing aggresome-like structures in N2a and GT1 cell cultures subjected to a mild treatment by lactacystin. It is noteworthy that the methods used to reveal PrP Sc differ markedly between the two studies. After paraformaldehyde fixation, cells were either treated with formic acid, permeabilized in methanol and immunostained with ICSM18 antibodies (Kristiansen et al., 2005) , or permeabilized with 0.1 % Triton X-100, treated with guanidium thiocyanate and immunostained with ICSM33 antibodies (this study). The visualization of PrP Sc incorporated into aggresomal structures in different infected cell culture models, using different proteasome inhibitors and distinct fixation/staining approaches, argues against experimental bias and reduces the likelihood that such observation may be limited to a particular model. In the CAD cell system, however, no cell-survival differences were observed between the infected and uninfected cultures under proteasome impairment.
Speculatively, the mechanisms envisioned to explain the presence of PrP Sc in the cytosolic compartment are basically twofold, i.e. transfer of PrP Sc accumulated at the luminal side by either retrotranslocation or cell-membrane leakage (Deriziotis & Tabrizi, 2008) . Based on current knowledge, the introduction of PrP Sc into the cytosolic compartment through the retrotranslocation machinery would imply transit through the biosynthetic compartment, including the ER, for which evidence is presently missing. Intriguingly, however, co-localization of PrP Sc aggregates and giantin has been reported to be a salient feature in the brain of infected transgenic mice coexpressing wild-type and enhanced green fluorescent protein-labelled PrP (Barmada & Harris, 2005) . Alternatively, it is conceivable that PrP Sc multimers or fragments of it produced by cellular hydrolases may destabilize the lipid membrane. Although this is as yet a poorly documented issue, two PrP peptides have been reported to have fusogenic activity in a liposome vesicle leakage assay (Pillot et al., 1997; Dupiereux et al., 2005) . Of possible relevance to the 'breaking and entering' hypothesis, it has been reported in a very recent study that polyglutamine fibrillar aggregates can be internalized by cells, where they gain access to the cytosolic compartment and become sequestered in aggresomal structures (Ren et al., 2009) .
A further question is whether the abnormal PrP 26K species that is produced in proteasome-impaired cells and exhibits unusual biochemical characteristics reminiscent of PrP Sc hallmarks might contribute to PrP Sc formation in TSE diseases, as proposed by some authors (Yedidia et al., 2001; Mishra et al., 2003) . Whilst proteasome inhibition led to accumulation to similar levels of unglycosylated -possibly retrotranslocated -PrP species in infected and uninfected CAD cells, we failed to detect any difference in the PrP Sc glycoform profiles of the untreated and treated cultures, even when cells were cultivated with proteasome inhibitors for several days. This result indicates that the insoluble PrP 26K is not particularly prone to conversion upon infection, leading us to propose that PrP 26K production and aggresome formation may occur independently of each other, i.e. by different mechanisms, in potentially distinct cell compartments.
The pathogenic role of the cytosolic PrP and the proteosomal pathway in prion diseases raises a number of points that deserve clarification. Until now, most studies pertaining to this question have been performed on genetically engineered cells in a non-infectious context. In future studies, it may be worth paying increased attention to animal and cell models that propagate truly infectious prions. Infectable cells such as CAD cells and primary neurons (Cronier et al., 2004) could provide new and helpful models for such investigations.
